valu usd unless otherwis note
continu deliv strong organ revenu
view continu deliv organ revenu growth peer
group new product libr heartmat mitraclip alin
key contributor abt revenu growth believ drive
sustain top-line growth remaind
reiter outperform rate rais pt
report organ revenu growth medic devic
highest growth segment follow diagnosi
establish pharmaceut nutrit
fx impact revenu approxim non-gaap ep
consensu fce ep beat
attribut lower ratio higher incom lower tax
rate partial off-set higher sg ratio
compar estim libr heart failur better
neuromodul fell short ww sale libr rbce
increas y/i libr sale estim
y/i continu expect libr fda approv
icgm label come shortli heart failur continu perform well
due us launch heartmat expect heart
failur grow high-teen y/i insert cardiac monitor icm
sale includ rhythm manag contribut sale
y/i structur heart achiev mid-teen
growth driven mitraclip grew y/i us
saw sequenti improv neuromodul declin
vs manag state neuromod sale forc
expans complet focus improv rep
product launch new product
diagnost grew mid-singl digit driven laboratori cl
cl grew y/i driven double-digit ou growth alin
famili earli stage launch alin instrument
hematolog molecular test europ work toward
regulatori approv addit core laboratori test us
instanc juli receiv fda approv alinity- diagnost
system blood plasma screen
rais ep guidanc prior
vs fce compani also rais organ sale growth
forecast prior ep guidanc
in-line estim consensu
increas pt prior new price target
reflect increas adjust ep estim
y/i y/i respect growth area
medic devic diagnost remain intact push
abt organ revenu ep growth ahead med-tech peer
believ level growth sustain near-term support
outperform rate new pt
price prior trade day market close estimate unless otherwis note
cours high-single-digit revenu growth
double-digit ep growth product cycl
refresh medic devic diagnost cost synergi
stj alr capit deploy acceler
debt repay push abt revenu ep growth
ahead sever med-tech peer revenu estim
impli cc revenu growth
believ upsid estim ep
estim repres double-digit cc growth
freestyl libr repres major sourc upsid us
launch proceed well growth
continu rapid pace expect fda approv
freestyl libr later year estim ww sale
cross pass
mitraclip sustain strong sale growth anoth
year mitraclip account structur
heart revenu ww mitraclip sale nearli
million last year could reach million
y/i exclud fx receiv fda approv mitraclip
secondari mitral regurgit march month
sooner compani commun publicli
next step reimburs could occur
end
laboratori diagnost grow market
next sever year laboratori
largest product categori within diagnost account
approxim segment revenu includ
diagnost revenu growth driven
roll-out alin instrument suit laboratori
diagnost europ past coupl
year launch advanc europ sinc
instrument test menu alin becam avail
sooner launch gather momentum
 receiv regulatori approv addit test
come month
bloomberg capit market estim upside/downside/target
arriv price target use weight
base sum-of-the-part ev/ebitda valuat impli
ebitda multipl price-to-earnings
multipl ep estim
key assumpt underli valuat
cc revenu growth cc growth
basi point increas oper margin year
continu debt reduct share
current trade around ep estim
arriv upsid scenario key differ
base-cas assumpt cc revenu growth
basi point ebit margin expans
year due higher revenu growth faster realiz
cost synergi integr stj alr
capit deploy share repurchas tuck-in
downsid scenario key differ
base-cas assumpt mid-single-digit cc organ
revenu growth basi point
ebit margin expans year due slower revenu
growth slower realiz cost synergi
arriv price target use weight base sum-of-the-part
ev/ebitda valuat impli ebitda multipl price-to-earnings
multipl ep abt growth profil justifi valuat
premium large-cap med-tech view price target basi outperform
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
